Kane Biotech Inc.
KNBIF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $8 | $28 | $413 | $126 |
| % Growth | -69.6% | -93.2% | 227.8% | – |
| Cost of Goods Sold | $14 | $74 | $370 | $213 |
| Gross Profit | -$5 | -$46 | $42 | -$87 |
| % Margin | -60.3% | -162.6% | 10.3% | -69.3% |
| R&D Expenses | $160 | $90 | $261 | $608 |
| G&A Expenses | $379 | $140 | $942 | $326 |
| SG&A Expenses | $379 | $140 | $942 | $326 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $538 | $230 | $1,204 | $933 |
| Operating Income | -$543 | -$275 | -$1,161 | -$1,021 |
| % Margin | -6,394.1% | -983.9% | -281.5% | -811% |
| Other Income/Exp. Net | -$64 | -$73 | -$57 | -$62 |
| Pre-Tax Income | -$607 | -$349 | -$1,218 | -$1,083 |
| Tax Expense | $0 | $0 | $0 | -$1,310 |
| Net Income | -$607 | -$349 | -$1,218 | -$1,083 |
| % Margin | -7,146.1% | -1,244.9% | -295.4% | -860.4% |
| EPS | -0.004 | -0.002 | -0.008 | -0.008 |
| % Growth | -71.4% | 74.1% | -6.6% | – |
| EPS Diluted | -0.004 | -0.002 | -0.008 | -0.008 |
| Weighted Avg Shares Out | 167,347 | 163,026 | 150,058 | 141,982 |
| Weighted Avg Shares Out Dil | 167,347 | 180,514 | 150,058 | 137,619 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8 | $6 | $2 | $1 |
| Interest Expense | $72 | $105 | $59 | $62 |
| Depreciation & Amortization | $36 | $46 | $48 | $64 |
| EBITDA | -$499 | -$197 | -$1,112 | -$957 |
| % Margin | -5,874.3% | -705.3% | -269.6% | -760.3% |